Fibrocell Science (FCSC) and Inovio Pharmaceuticals (INO) Critical Review

Fibrocell Science (NASDAQ: FCSC) and Inovio Pharmaceuticals (NASDAQ:INO) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Fibrocell Science and Inovio Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fibrocell Science 0 0 3 0 3.00
Inovio Pharmaceuticals 0 2 8 0 2.80

Fibrocell Science currently has a consensus target price of $5.53, indicating a potential upside of 169.92%. Inovio Pharmaceuticals has a consensus target price of $20.20, indicating a potential upside of 250.09%. Given Inovio Pharmaceuticals’ higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Fibrocell Science.

Earnings and Valuation

This table compares Fibrocell Science and Inovio Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Fibrocell Science $350,000.00 86.22 -$15.29 million ($1.96) -1.05
Inovio Pharmaceuticals $35.37 million 14.72 -$73.74 million ($1.08) -5.34

Fibrocell Science has higher revenue, but lower earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Fibrocell Science has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.

Institutional & Insider Ownership

54.7% of Fibrocell Science shares are held by institutional investors. Comparatively, 25.0% of Inovio Pharmaceuticals shares are held by institutional investors. 2.1% of Fibrocell Science shares are held by insiders. Comparatively, 10.6% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Fibrocell Science and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fibrocell Science N/A -293.07% -91.03%
Inovio Pharmaceuticals -153.46% -63.67% -46.77%

Summary

Inovio Pharmaceuticals beats Fibrocell Science on 8 of the 13 factors compared between the two stocks.

About Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit